本文選題：骨髓增生異常綜合征 + 鐵蛋白　； 參考：《山東醫(yī)藥》2017年48期

【摘要】：目的探討初發(fā)骨髓增生異常綜合征(MDS)患者血清鐵蛋白(SF)水平變化及臨床意義。方法選取初發(fā)MDS患者50例,其中RA型6例、RARS型4例、RCMD型20例、RAEB-1型13例、RAEB-2型7例,極低危3例、低危8例、中危20例、高危15例、極高危4例�；颊叻謩e于輸血前及累計(jì)輸注紅細(xì)胞達(dá)10、20、30 U時(shí)取血,采用放射免疫法檢測血清SF水平,計(jì)算SF變化量(SFΔ);分析血清SFΔ與患者輸血量、臨床分型、危險(xiǎn)分層的關(guān)系。輸注紅細(xì)胞達(dá)30 U時(shí),將患者分為SFΔ≥2 000 ng/m L組和2 000 ng/m L組,比較兩組預(yù)后。結(jié)果輸血前RARS、RAEB-1、RAEB-2型患者血清SF水平均高于RA、RCMD型患者(P均0.05),高危、極高�；颊呔哂跇O低危、低危及中�；颊�(P均0.05)。RAEB-1、RAEB-2型患者在輸注紅細(xì)胞量為20、30 U時(shí)血清SFΔ均低于其他各型(P均0.05)。高危、極高�；颊咻斪⒓t細(xì)胞達(dá)30 U時(shí)血清SFΔ均低于其他危險(xiǎn)度患者(P均0.05)。兩組均隨訪至2016年6月,輸注紅細(xì)胞達(dá)30 U時(shí)SFΔ≥2 000 ng/m L組的MDS/急性髓系白血病(AML)轉(zhuǎn)化率低于SFΔ2 000 ng/m L組(P0.01),中位總體生存時(shí)間長于SFΔ2 000 ng/m L組(P0.01)。結(jié)論初發(fā)RARS、REAB-1、RAEB-2型及高危、極高危MDS患者血清SF水平均高于其他分型及危險(xiǎn)度者;隨著輸血量的增加,RAEB-1、RAEB-2型及高危、極高�；颊哞F過載程度均高于其他分型及危險(xiǎn)度者;血清SF水平變化對MDS患者預(yù)后有一定的預(yù)測作用。
[Abstract]:Objective to investigate the changes and clinical significance of serum ferritin (SF) levels in patients with primary myelodysplastic syndromes (MDS).Methods A total of 50 patients with primary MDS were selected, including 6 patients with RA type, 4 patients with RCMD type, 20 patients with RCMD type and 13 patients with RAEB-1 type, 7 patients with very low risk, 8 patients with low risk, 20 patients with moderate risk, 15 patients with high risk and 4 patients with very high risk.The serum SF level was measured by radioimmunoassay and the changes of SF 螖 were calculated, and the relationship between serum SF 螖 and blood transfusion volume, clinical type and risk stratification were analyzed.The patients were divided into two groups: SF 螖 鈮，

本文編號：1759159